Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Sept. Drug Price Settlement Rate at 92.6% as Big Hospitals, Pharmacies Take Quantum Leap
A health ministry survey found that pharmaceutical wholesalers had agreed on delivery drug prices with customer healthcare providers for 92.6% of their transactions as of the end of September, six months after the FY2014 NHI price revision, Jiho has learned.…
To read the full story
Related Article
- MHLW Official Says Penalty Rule Needs Review, Frowns on Sanguine Outlook for Annual Drug Price Cut
November 17, 2014
- MHLW Official Says Price Settlement Rate Apparently Topped 90% at End of Sept., but Annual Revisions Unrealistic for “Exhausted” Wholesalers
October 28, 2014
- Drug Price Settlement Rate Might Hit 70% in September: Wholesaler Exec
September 3, 2014
Related LEXICON
REGULATORY
- Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
- DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform
January 23, 2026
- Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus
January 23, 2026
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…